Evidence map›Paper›PMID 41927498›Full record

ArticleCancer medicine2026

Regrowth Patterns in Glioblastoma-Survival and Predictors.

Jonas A Feldheim, Jana Grieger, Teresa Schmidt, Christoph Oster, Julia J Feldheim, Pia Wepner, Elke Hattingen, Carsten Hagemann, Ulrich Sure, Ulrich Herrlinger and 8 more

Abstract read
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jonas A FeldheimDivision of Clinical Neuro-Oncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.ORCID https://orcid.org/0000-0002-7297-4854
Jana GriegerDivision of Clinical Neuro-Oncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.
Teresa SchmidtDivision of Clinical Neuro-Oncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.
Christoph OsterDivision of Clinical Neuro-Oncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.
Julia J FeldheimDepartment of Neurosurgery, University Hospital Essen, Essen, Germany.
Pia WepnerDivision of Clinical Neurooncology, Department of Neurology, Medical Center Bonn, Bonn, Germany.
Elke HattingenInstitute of Neuroradiology, Goethe University Hospital, Frankfurt am Main, Germany.
Carsten HagemannSection Experimental Neurosurgery, Department of Neurosurgery, University Hospital Würzburg, Würzburg, Germany.
Ulrich SureDepartment of Neurosurgery, University Hospital Essen, Essen, Germany.
Ulrich HerrlingerDivision of Clinical Neurooncology, Department of Neurology, Medical Center Bonn, Bonn, Germany.
Martin StuschkeDepartment of Radiation Oncology, University Hospital Essen, Essen, Germany.
Björn SchefflerGerman Cancer Consortium (DKTK), Partner Site University Medicine Essen, Essen, Germany.
Cornelius DeuschlInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Christoph KleinschnitzDivision of Clinical Neuro-Oncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.
Lazaros LazaridisDivision of Clinical Neuro-Oncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.
Sied KebirDivision of Clinical Neuro-Oncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.
Niklas SchäferDivision of Clinical Neurooncology, Department of Neurology, Medical Center Bonn, Bonn, Germany.
Martin GlasDivision of Clinical Neuro-Oncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.

Funding

Universität Duisburg-Essen
6 · The paper itself

Abstract

Glioblastomas (GBM) can recur in different ways. While local recurrence is most common, some GBM recur at distant sites or simultaneously at multiple sites. However, the consequences of different regrowth patterns for the clinical course and the factors that might influence regrowth patterns or different modalities of recurrence remain unclear. We wondered (1) whether a more accurate analysis of regrowth patterns helps to detect subgroups of GBM patients, (2) if evaluation of relapse patterns correlates with differences in survival, and (4) whether we can identify predictors for distinct regrowth patterns. Therefore, we retrospectively collected demographic data, as well as tumor- and patient-characteristics, from 251 patients treated at two institutions and characterized their recurrence patterns by analyzing Magnetic Resonance Imaging data. We observed distinct differences in patients' overall and progression-free survival with respect to multicentric and multifocal recurrences, further supporting the hypothesis that these recurrences develop differently. Several tumor relapse patterns were associated with patients' progression-free and overall survival (e.g., unifocal local and multicentric recurrences; p < 0.05), even when other known prognostic factors were taken into account. TTFields were associated with prolonged progression-free survival (mPFS 7.2 months vs. 4.8 months, p = 0.03). They were predictive of a higher frequency of non-local recurrence patterns (OR 0.16, p = 0.02) and longer time to development of a local recurrence after subtotal tumor resection (mPFS 11.1 months vs. 5.2 months; p = 0.01). This can be interpreted as a sign of improved local control.

Indexed as

Brain NeoplasmsGlioblastomaNeoplasm Recurrence, LocalAdultAgedFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedPrognosisProgression-Free SurvivalRetrospective StudiesdistantlocalmulticentricmultifocalprogressionrecurrenceTTFields

Identifiers

PMID41927498
PMCPMC13052026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.